Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + paclitaxel + ramucirumab
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination of three drugs: irinotecan (a topoisomerase I inhibitor), paclitaxel (a microtubule stabilizing agent), and ramucirumab (a VEGFR2 antagonist). While ramucirumab is approved in combination with paclitaxel for gastric cancer and separately in combination with irinotecan (FOLFIRI) for colorectal cancer, the three-drug combination does not appear to be a standard regimen based on available information.
02
Targets
MicrotubuleTOP1 (DNA Topoisomerase I)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on irinotecan + paclitaxel + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + paclitaxel + ramucirumab.